Clinical trial
Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer
NCT00121745 · Epeius Biotechnologies, Industry · Terminated
Key facts
| NCT number | NCT00121745 |
|---|---|
| Title | Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer |
| Official title | Phase I Evaluation of Safety of Intravenous Infusion of a Pathotropic Vector Bearing a Cytocidal Cyclin G1 Construct (Rexin-G) as Intervention for Locally Advanced and Metastatic Pancreatic Cancer Refractory to Standard Chemotherapy |
| Lead sponsor | Epeius Biotechnologies, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Genetic |
| Interventions | Rexin-G Dose 1, Rexin-G Dose 2, Rexin-G Dose 3, Rexin-G Dose 4 |
| Enrollment | 12 |
| Start date | Jul 1, 2005 |
| Completion | Jul 1, 2007 |
| First posted | Jul 21, 2005 |
| Last update posted | Dec 20, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: